H.C. Wainwright lowered the firm’s price target on ALX Oncology (ALXO) to $2 from $5 and keeps a Buy rating on the shares. The company announced its decision to discontinue the development of evorpacept in gastric and gastroesophageal cancers based on the FDA’s feedback, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALXO:
- ALX Oncology Reports Q1 2025 Financial Results
- ALX Oncology reports Q1 EPS (58c) vs (71c) last year
- ALX Oncology price target lowered to $1.20 from $2.20 at UBS
- ALX Oncology reports ‘encouraging’ final results from Phase 1 evorpacept trial
- ALX Oncology reports ASPEN-03, ASPEN-04 trials did not meet primary endpoints